Related Experiment Video
Updated: Oct 3, 2025
08:08
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
16.5K
Proteomics technologies for cancer liquid biopsies.
Zhiyong Ding1, Nan Wang2, Ning Ji3,4
1Mills Institute for Personalized Cancer Care, Fynn Biotechnologies Ltd., Gangxing 3rd Rd, High-Tech and Innovation Zone, Bldg. 2, Rm. 2201, Jinan City, Shandong Province, 250101, P. R. China. zhiyong.ding@fynnbio.com.
Molecular Cancer
|February 16, 2022
Summary
Deep proteome profiling of liquid biopsies offers real-time cancer insights, surpassing DNA analysis. Novel high-plex proteomic technologies are crucial for advancing cancer biomarker discovery and clinical applications.
Area of Science:
- Proteomics
- Cancer Biology
- Biomarker Discovery
Background:
- DNA alterations alone do not fully explain protein changes in cancer.
- Deep proteome profiling in liquid biopsies can provide real-time, clinically relevant cancer progression data.
- Proteomic discoveries have lagged behind genomic technologies due to sample complexity and technological limitations.
Purpose of the Study:
- To review high-plex proteomic technologies for cancer liquid biopsy analysis.
- To highlight the demand for novel protein technologies in biomarker discovery.
- To discuss advancements facilitating early cancer detection, diagnosis, prognosis, and monitoring.
Main Methods:
- Review of traditional and innovative high-plex proteomics technologies.
- Analysis of methods capable of measuring hundreds of proteins simultaneously.
- Inclusion of mass spectrometry (MS), antibody/antigen arrays, aptamer-based assays, proximity extension assay (PEA), and reverse phase protein arrays (RPPA).
Main Results:
- High-plex proteomics technologies are rapidly developing for liquid biopsy analysis.
- These technologies range from established MS and arrays to novel aptamer, PEA, and RPPA methods.
- Advances enable comprehensive proteomic profiling for various clinical applications.
Conclusions:
- Deep proteome profiling is essential for understanding cancer progression and complementing genomic data.
- Novel proteomic technologies are critical for overcoming current limitations in biomarker discovery.
- Continued technological development in high-plex proteomics will significantly impact cancer diagnostics and patient management.
